Taiko Pharmaceutical
4574.TPharmaceutical
Filed as TAIKO PHARMACEUTICAL CO.,LTD. (2022-08–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥5.6bn | ¥5.5bn | ¥5.4bn | ¥4.6bn | ¥10.6bn | ¥17.1bn |
| Operating income | ¥282m | ¥501m | −¥1.0bn | −¥3.0bn | −¥5.0bn | — |
| Ordinary income | ¥332m | ¥947m | −¥1.3bn | −¥3.3bn | −¥5.9bn | ¥5.5bn |
| Total assets | ¥11.5bn | ¥12.1bn | ¥12.2bn | ¥14.3bn | ¥21.9bn | ¥31.0bn |
| Net assets / equity | ¥8.0bn | ¥7.4bn | ¥6.0bn | ¥7.5bn | ¥12.4bn | ¥22.2bn |
| EPS (basic) | ¥15.56 | ¥23.34 | ¥-78.63 | ¥-113.64 | ¥-213.03 | ¥89.57 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 3
| Period | Form | Figures |
|---|---|---|
| 2022-01-01 → 2022-12-31 | Annual | 207 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 49 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 73 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Infection Control Business | ¥619m | −¥254m |
| Pharmaceuticals Business | ¥5.8bn | ¥1.6bn |
| Other segments | ¥5m | −¥22m |
| Adjustments & eliminations | — | −¥837m |
| Total | ¥6.4bn | ¥1.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.